|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2010-9-29
|
|
pubmed:abstractText |
Sunitinib is a multitargeted, oral tyrosine kinase inhibitor with antitumour and antiangiogenic activity. We investigated the safety and pharmacokinetics of sunitinib in combination with irinotecan in patients with advanced, refractory solid tumours.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1532-1827
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
28
|
|
pubmed:volume |
103
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
993-1000
|
|
pubmed:dateRevised |
2011-9-30
|
|
pubmed:meshHeading |
pubmed-meshheading:20717111-Adult,
pubmed-meshheading:20717111-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20717111-Camptothecin,
pubmed-meshheading:20717111-Drug Administration Schedule,
pubmed-meshheading:20717111-Female,
pubmed-meshheading:20717111-Humans,
pubmed-meshheading:20717111-Indoles,
pubmed-meshheading:20717111-Male,
pubmed-meshheading:20717111-Maximum Tolerated Dose,
pubmed-meshheading:20717111-Middle Aged,
pubmed-meshheading:20717111-Neoplasms,
pubmed-meshheading:20717111-Pyrroles,
pubmed-meshheading:20717111-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.
|
|
pubmed:affiliation |
Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, Amsterdam NL-1081 HV, The Netherlands. e.boven@vumc.nl
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
